New BIH Chief Executive Officer starts work
Today, medical professor Erwin Böttinger takes office as BIH’s new Chief Executive Officer. He succeeds Ernst Th. Rietschel, who has led BIH since its founding in 2013. Upon taking office at BIH, Böttinger is also appointed professor of personalized medicine at Charité - Universitätsmedizin Berlin. As full-time Chief Executive Officer, Böttinger assumes responsibility for the Executive Board’s activities and will take charge of strategic and scientific planning and monitor their success, together with his counterparts at MDC and Charité, the dean of Charité, and a full-time administrative board member. The Chief Executive Officer is appointed by the BIH’s Board of Directors for a period of five years. In 1987, after completing his medical studies at Friedrich-Alexander Universität in ErIangen-Nuremberg, Erwin Böttinger moved to the U.S., where he conducted research at several institutions including Massachusetts General Hospital, Harvard Medical School and National Cancer Institute in Bethesda. From 2000 to 2004 he was Director of the Biotechnology Center at Albert Einstein College of Medicine in New York. In 2004, Böttinger took up a position at Icahn School of Medicine at Mount Sinai, New York, where he has been Director of the Charles Bronfman Institute for Personalized Medicine since 2007. The main focus of kidney specialist Böttinger’s research is the field of personalized medicine. This involves using approaches from genomics and bioinformatics to identify molecular disease mechanisms, with the aim of improving prevention, diagnosis and treatment. The BIH will benefit from this special expertise.